603367 辰欣药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入850,351-7.59%3,444,7173,981,5724,462,3494,066,088
减:营业总成本690,430-6.91%3,089,2053,483,4633,866,6833,717,618
    其中:营业成本357,362-3.60%1,657,3431,729,0941,839,0241,789,293
               财务费用(4,569)-19.89%(30,123)(32,483)(33,671)(27,876)
               资产减值损失(28,091)-33.19%(59,132)(56,026)(73,497)(16,462)
公允价值变动收益(13,177)-346.75%39,68010,528(10,375)(3,120)
投资收益28,2142.11%123,46862,30444,11818,680
    其中:对联营企业和合营企业的投资收益------(484)132(753)
营业利润144,247-10.05%499,882572,048592,578364,583
利润总额143,854-10.10%496,195575,773595,857366,191
减:所得税费用11,742-23.80%70,57660,83370,43013,920
净利润132,112-8.64%425,619514,940525,426352,271
减:非控股权益1,36728.09%4,3696,0344,0882,313
股东净利润130,745-8.92%421,249508,906521,338349,959

市场价值指针
每股收益 (元) *0.290-9.38%0.9301.1201.1500.770
每股派息 (元) *----0.3480.4400.4360.335
每股净资产 (元) *13.9633.69%13.67513.14112.64911.763
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容